Prescription medicine
Remestemcel-l-rknd Brand names: Ryoncil
Remestemcel-l-rknd (Ryoncil) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the remestemcel-l-rknd FDA label on DailyMed (effective September 11, 2025); every remestemcel-l-rknd label on DailyMed.
Highlights of the record
FDA label of September 11, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageRYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Forms and strengths
Kit.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
What is remestemcel-l-rknd used for?
From the label: indications and usageRYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. RYONCIL is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older.
Source: FDA drug label (RYONCIL), Mesoblast, effective September 11, 2025 (SPL set a4e0918f-7444-4694-adeb-d38d98345659), via openFDA; the full label on DailyMed
Is there a generic for remestemcel-l-rknd (Ryoncil)?
No generic remestemcel-l-rknd is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the remestemcel-l-rknd label say about other medicines?
The remestemcel-l-rknd label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Dimethyl sulfoxide | contraindications | CONTRAINDICATIONS Do not use RYONCIL in patients with known hypersensitivity to dimethyl sulfoxide (DMSO) or porcine and bovine proteins. |
Source: FDA drug label (RYONCIL), Mesoblast, effective September 11, 2025 (SPL set a4e0918f-7444-4694-adeb-d38d98345659), via openFDA; the full label on DailyMed
What next?
- Check an interaction
- what two or more labels say about each other